Comparison · NCT02020889-82f2de4d
Mepolizumab 300mg vs Placebo: Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Mepolizumab 300mg vs Placebo: Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period. Trial comparisons, record NCT02020889-82f2de4d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02020889-82f2de4d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.191 | 0.115 | 0.3 | wilson | |
| Risk in group 2 | 0.0147 | 0.0026 | 0.0787 | wilson | |
| Risk difference, group 1 minus group 2 | 0.176 | 0.0772 | 0.286 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 13 | 1.75 | 96.6 | log | |
| Odds ratio, group 1 over group 2 | 15.8 | 2.01 | 125 | log | |
| Number needed to treat, for one more participant with the outcome on Mepolizumab 300mg than on Placebo | 5.67 | 3.5 | 13 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Mepolizumab 300mg | Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48. | 13 | 68 | OG001 |
| Group 2 | Placebo | Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48. | 1 | 68 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period
- Description
The number of participants who achieved remission (i.e., BVAS=0 and prednisolone/prednisone\<=4 mg/day) within the first 24 weeks and remain in remission for the remainder of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.
- Time frame
- Up to Week 52
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
- NCT number
- NCT02020889
- Phases
- PHASE3
- Conditions
- Churg-Strauss Syndrome
- Interventions
- Mepolizumab, Placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2018-01-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02020889?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02020889-82f2de4d